Cell surface phenotype of MER cell line
| mAb . | Distribution (Function) . | MER . | MER + PWM . |
|---|---|---|---|
| Percentage of Positive Cells (RFI) . | |||
| CD3 | Mature T cells (associated with TCR) | 0 (1.07) | 0 (1.09) |
| CD5 | T cells, B-cell subset | 0 (0.97) | 0 (1.0) |
| CD9 | Platelets, pre-B cells, activated T cells | 21 (8.9) | 60 (34) |
| HLA-DR | (Class II MHC antigen) | 100 (6.4) | 100 (6.4) |
| CD10 | Lymphoid progenitors (common acute lymphoblastic leukemia antigen [CALLA]) | 0 (0.92) | 0 (1.0) |
| CD11a | Leukocytes (LFA-1, αL integrin chain) | 62 (9.1) | 75 (8.1) |
| CD11b | Granulocytes, monocytes, NK cells (mac-1, αM integrin chain) | 0 (1.0) | 0 (0.99) |
| CD18 | Leukocytes (β2 integrin chain) | 88 (14.3) | 94 (18.7) |
| CD19 | Pan B-cell | 94 (14.9) | 98 (28) |
| CD20 | Pan B-cell | 100 (6.3) | 100 (9.8) |
| HLA-A, B, and C | (Class I MHC antigen) | 100 (34.9) | 100 (16.5) |
| CD34 | Hematopoietic stem cells and progenitors | 0 (0.92) | 0 (1.0) |
| CD38 | Plasma cells, activated T cells | 95 (19.8) | 95 (18.3) |
| CD49d | Monocytes, B cells, T cells (VLA-4 α chain, α4 integrin chain) | 97 (23.2) | 99 (26.6) |
| CD54 | Activated cells (ICAM-1) | 90 (14.3) | 97 (18.7) |
| CD56 | NK cells and T cells, some myeloma plasma cells (isoform of N-CAM) | 0 (1.16) | 0 (0.94) |
| CD80 | Activated B cells and T cells, Burkitt's lymphomas (B:T cell interactions, B7) | 100 (11.4) | 100 (24.6) |
| CD138 | Plasma cells, syndecan-1, BB4 | 78 (5.3) | 28 (1.8) |
| Surface immunoglobulin | B cells | 100 (2.7) | 100 (2.2) |
| mAb . | Distribution (Function) . | MER . | MER + PWM . |
|---|---|---|---|
| Percentage of Positive Cells (RFI) . | |||
| CD3 | Mature T cells (associated with TCR) | 0 (1.07) | 0 (1.09) |
| CD5 | T cells, B-cell subset | 0 (0.97) | 0 (1.0) |
| CD9 | Platelets, pre-B cells, activated T cells | 21 (8.9) | 60 (34) |
| HLA-DR | (Class II MHC antigen) | 100 (6.4) | 100 (6.4) |
| CD10 | Lymphoid progenitors (common acute lymphoblastic leukemia antigen [CALLA]) | 0 (0.92) | 0 (1.0) |
| CD11a | Leukocytes (LFA-1, αL integrin chain) | 62 (9.1) | 75 (8.1) |
| CD11b | Granulocytes, monocytes, NK cells (mac-1, αM integrin chain) | 0 (1.0) | 0 (0.99) |
| CD18 | Leukocytes (β2 integrin chain) | 88 (14.3) | 94 (18.7) |
| CD19 | Pan B-cell | 94 (14.9) | 98 (28) |
| CD20 | Pan B-cell | 100 (6.3) | 100 (9.8) |
| HLA-A, B, and C | (Class I MHC antigen) | 100 (34.9) | 100 (16.5) |
| CD34 | Hematopoietic stem cells and progenitors | 0 (0.92) | 0 (1.0) |
| CD38 | Plasma cells, activated T cells | 95 (19.8) | 95 (18.3) |
| CD49d | Monocytes, B cells, T cells (VLA-4 α chain, α4 integrin chain) | 97 (23.2) | 99 (26.6) |
| CD54 | Activated cells (ICAM-1) | 90 (14.3) | 97 (18.7) |
| CD56 | NK cells and T cells, some myeloma plasma cells (isoform of N-CAM) | 0 (1.16) | 0 (0.94) |
| CD80 | Activated B cells and T cells, Burkitt's lymphomas (B:T cell interactions, B7) | 100 (11.4) | 100 (24.6) |
| CD138 | Plasma cells, syndecan-1, BB4 | 78 (5.3) | 28 (1.8) |
| Surface immunoglobulin | B cells | 100 (2.7) | 100 (2.2) |
RFI indicates relative fluorescence intensity. The percentage and level of expression of 19 cell surface molecules is shown for MER and MER + PWM. MER cells were labeled with mAbs specific for each cell surface molecule as described in “Materials and methods.” Labeled cells were analyzed by flow cytometry. The data show the percentage of positive cells and the RFI. RFI = 10(Experimental MFI/256 − Control MFI/256) where 256 indicates the number of gates used in the analysis and MFI indicates mean fluorescense intensity.